Galera Therapeutics (GRTX) Competitors $0.02 +0.00 (+2.27%) As of 08/15/2025 11:54 AM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsInsider TradesOptions ChainSEC FilingsShort InterestTrendsBuy This Stock GRTX vs. CDIO, ALZN, MBIO, MYNZ, AEZS, NLSP, JBIO, ARTL, INAB, and SBFMShould you be buying Galera Therapeutics stock or one of its competitors? The main competitors of Galera Therapeutics include Cardio Diagnostics (CDIO), Alzamend Neuro (ALZN), Mustang Bio (MBIO), Mainz Biomed (MYNZ), Aeterna Zentaris (AEZS), NLS Pharmaceutics (NLSP), Jade Biosciences (JBIO), Artelo Biosciences (ARTL), IN8bio (INAB), and Sunshine Biopharma (SBFM). These companies are all part of the "pharmaceutical products" industry. Galera Therapeutics vs. Its Competitors Cardio Diagnostics Alzamend Neuro Mustang Bio Mainz Biomed Aeterna Zentaris NLS Pharmaceutics Jade Biosciences Artelo Biosciences IN8bio Sunshine Biopharma Galera Therapeutics (NASDAQ:GRTX) and Cardio Diagnostics (NASDAQ:CDIO) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, institutional ownership, earnings, media sentiment, profitability, analyst recommendations, risk and valuation. Do institutionals and insiders believe in GRTX or CDIO? 50.8% of Galera Therapeutics shares are owned by institutional investors. Comparatively, 8.1% of Cardio Diagnostics shares are owned by institutional investors. 12.9% of Galera Therapeutics shares are owned by company insiders. Comparatively, 22.3% of Cardio Diagnostics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Is GRTX or CDIO more profitable? Galera Therapeutics has a net margin of 0.00% compared to Cardio Diagnostics' net margin of -30,465.10%. Galera Therapeutics' return on equity of 0.00% beat Cardio Diagnostics' return on equity.Company Net Margins Return on Equity Return on Assets Galera TherapeuticsN/A N/A -99.34% Cardio Diagnostics -30,465.10%-76.14%-68.47% Do analysts recommend GRTX or CDIO? Cardio Diagnostics has a consensus target price of $60.00, indicating a potential upside of 1,552.89%. Given Cardio Diagnostics' stronger consensus rating and higher possible upside, analysts plainly believe Cardio Diagnostics is more favorable than Galera Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Galera Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Cardio Diagnostics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has stronger earnings & valuation, GRTX or CDIO? Cardio Diagnostics has higher revenue and earnings than Galera Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGalera TherapeuticsN/AN/A-$59.08M-$0.19-0.12Cardio Diagnostics$19.90K317.18-$8.38MN/AN/A Does the media prefer GRTX or CDIO? In the previous week, Cardio Diagnostics had 5 more articles in the media than Galera Therapeutics. MarketBeat recorded 5 mentions for Cardio Diagnostics and 0 mentions for Galera Therapeutics. Cardio Diagnostics' average media sentiment score of 0.53 beat Galera Therapeutics' score of 0.00 indicating that Cardio Diagnostics is being referred to more favorably in the news media. Company Overall Sentiment Galera Therapeutics Neutral Cardio Diagnostics Positive Which has more volatility and risk, GRTX or CDIO? Galera Therapeutics has a beta of 1.91, indicating that its share price is 91% more volatile than the S&P 500. Comparatively, Cardio Diagnostics has a beta of 2.96, indicating that its share price is 196% more volatile than the S&P 500. SummaryCardio Diagnostics beats Galera Therapeutics on 10 of the 13 factors compared between the two stocks. Get Galera Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for GRTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding GRTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GRTX vs. The Competition Export to ExcelMetricGalera TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.70M$778.25M$5.72B$9.79BDividend YieldN/A4.84%3.91%4.13%P/E Ratio-0.061.1831.1425.06Price / SalesN/A25.64416.7890.80Price / CashN/A19.5636.7858.67Price / Book-0.016.599.086.18Net Income-$59.08M-$4.67M$3.26B$265.11M7 Day PerformanceN/A3.22%7.39%4.22%1 Month PerformanceN/A3.30%4.22%0.77%1 Year PerformanceN/A15.26%30.30%24.69% Galera Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GRTXGalera TherapeuticsN/A$0.02+2.3%N/A-70.8%$1.70MN/A-0.0630Gap UpCDIOCardio Diagnostics2.6201 of 5 stars$3.98-0.3%$60.00+1,407.5%-71.4%$6.92M$19.90K0.001News CoverageEarnings ReportAnalyst UpgradeShort Interest ↑ALZNAlzamend Neuro2.7465 of 5 stars$2.38+2.6%$180.00+7,463.0%-87.0%$6.90MN/A0.004Short Interest ↑Gap DownMBIOMustang Bio1.2275 of 5 stars$1.57+4.0%N/A-90.4%$6.88MN/A-0.02100Positive NewsEarnings ReportShort Interest ↓MYNZMainz Biomed2.6713 of 5 stars$1.50+5.6%$14.00+833.3%-86.7%$6.87M$893.99K-0.0230News CoverageShort Interest ↑AEZSAeterna ZentarisN/A$3.82-2.1%N/A-49.6%$6.85M$2.37M-0.2620NLSPNLS PharmaceuticsN/A$1.90+0.7%N/A+1,305.4%$6.84MN/A0.006News CoverageShort Interest ↓Gap UpJBIOJade Biosciences2.301 of 5 stars$7.94+8.9%$15.00+88.9%N/A$6.68MN/A-0.1320News CoveragePositive NewsEarnings ReportAnalyst ForecastAnalyst RevisionGap UpARTLArtelo Biosciences2.8855 of 5 stars$9.48-4.5%$24.00+153.2%+28.6%$6.64MN/A-0.535Earnings ReportShort Interest ↓Gap DownINABIN8bio4.0732 of 5 stars$2.17+3.8%$180.00+8,194.9%-88.7%$6.57MN/A-0.1620Positive NewsShort Interest ↓SBFMSunshine Biopharma2.3814 of 5 stars$1.43-2.1%$15.00+949.0%-49.0%$6.52M$36.23M-0.013Negative NewsEarnings ReportGap Down Related Companies and Tools Related Companies CDIO Competitors ALZN Competitors MBIO Competitors MYNZ Competitors AEZS Competitors NLSP Competitors JBIO Competitors ARTL Competitors INAB Competitors SBFM Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GRTX) was last updated on 8/17/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredNew Federal Land Rush About to Start?A $100 Trillion Wealth Shift Is Already Underway Lithium. Oil. Gold. Trillions in U.S. resources are being ...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Galera Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Galera Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access